
    
      The primary objective of the study is to describe the safety profile of radium-223 dichloride
      in patients having castration-resistent prostate cancer with symptomatic bone metastases and
      who are treated in routine clinical practice in Taiwan.

      The secondary objective is to assess the effectiveness of radium-223 dichloride in these
      patients.
    
  